Sublingual immunotherapy (SLIT) 
Introduction
Since immunotherapy was fi rst introduced for allergic rhinitis in 1911, 1 many routes of administration have been investigated. Subcutaneous injection immunotherapy (SCIT) has been the most commonly used worldwide, as its effi cacy has been established in a large number of trials. 2 However, safety concerns, coupled with poor patient tolerance for injections and frequent offi ce visits, sparked an interest in exploring noninjection routes of administration. Sublingual immunotherapy (SLIT) has become the most popular of these. In 1998, the World Health Organization 3 and the European Academy of Allergology and Clinical Immunology 4 concluded that SLIT is a viable alternative to SCIT.
Multiple randomized and double-blind, placebocontrolled trials assessing the effi cacy and safety of SLIT have been published in the European literature. Th e numbers of these published trials are greatly increasing each year. 5 In the United States, however, there is a paucity of published SLIT research.
A number of SLIT dosing and escalation regimens exist worldwide. Th ese regimens have not been standardized with regard to antigen dose or rapidity of escalation. 6 A recent consensus dosing regimen for SLIT escalation recommended a 12-week escalation period. 7 In the Rhinology Division of the Department of Otolaryngology-Head and Neck Surgery at the Medical University of South Carolina (MUSC), multiple-antigen SLIT has been off ered to polysensitized patients with recalcitrant allergy symptoms for nearly 6 years. It should be noted that the MUSC Rhinology Division also continues to off er SCIT. Study subjects were counseled regarding both forms of immunotherapy and were given an option for treatment with either SLIT or SCIT. Th e polytherapy SLIT dosing and escalation protocol used in this study was based primarily on long-established otolaryngic allergy dosing and escalation protocols for SCIT as described by King et al. 8 With the improved safety profi le of SLIT when compared to that of SCIT, Volume 90, Number 9 www.entjournal.com ■ E17
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92%) displayed positive reactions as indicated by an endpoint of ≥3 to one or more of the antigens tested. Th ree patients underwent prick testing only and, therefore, their positive reactions could not be quantifi ed. All of the patients in the cohort had experienced inadequate control of allergic symptoms on avoidance measures plus pharmacotherapy. Subsequently, they were off ered either SCIT or SLIT and ultimately chose SLIT. All patients who were off ered immunotherapy were advised regarding the effi cacy, safety, and side eff ect profi le of SLIT as compared to SCIT and were also informed that SLIT is currently not approved by the U.S. Food and Drug Administration. Prior to beginning treatment, each patient signed written informed consent.
Treatment vials were prepared per institution protocol (fi gure 1). Most patients had positive reactions to multiple antigens. For such patients, the highest endpoint reaction was identifi ed. Dropper-top treatment vials were then prepared with all positive antigens based on the endpoint of the highest reactor. Treatment vials were made in 5-fold dilutions, based on a previously established otolaryngic allergy SCIT vial preparation protocol. 8 Antigens for vial preparation were drawn from the MUSC stock of standardized commercial allergy extracts (Greer Laboratories; Lenoir, N.C.).
Several diff erent SLIT protocols are currently in use worldwide. In the MUSC SLIT protocol, the escalation MUSC has decreased the timing of escalation to approximately 5 weeks. 5, 7 Overall, the clinical impression in the MUSC Rhinology Division was that patients receiving SLIT appeared to have shown improvement. Th is clinical impression prompted a previous study to investigate a small cohort of MUSC allergy patients receiving SLIT from baseline to the maintenance phase of treatment with regard to subjective symptom response. Th e data from that study indicated a statistically signifi cant symptom reduction in 12 of the 14 domains listed on the standardized miniRhinoconjuctivitis Questionnaire (m-RQLQ). 9 Th e study described in this article investigated a larger cohort (N = 38) to assess symptom improvement and medication use immediately following polytherapy SLIT antigen escalation in order to determine the timing of clinical improvement. To the knowledge of the MUSC Rhinology Division, no other SLIT studies have investigated polytherapy SLIT and its eff ects in the escalation phase. As a secondary focus, maintenance phase data for a subset of patients in the same cohort were also examined.
Approval for this study was granted by the Institutional Review Board of the Medical University of South Carolina.
Patients and methods
A retrospective review utilizing allergy symptom and medication-use surveys prospectively collected from patients undergoing SLIT was performed. Th e study cohort included patients experiencing symptoms of allergic rhinitis who were subsequently found to have positive reactions to a panel of common inhalant allergens. Th e panel included perennial allergens such as cat, dog, roach, and dust mite. It also included fungi and pollens of weeds, trees, and grasses that were specifically chosen for the Southeastern United States coastal region (table 1) .
Th e majority (n = 27) of the patients underwent modifi ed quantitative testing, which is a blended technique that incorporates both skin prick and intradermal testing and is the preferred testing method in the MUSC Rhinology Division. 10 A small number of patients (n = 5) tested early in the series underwent intradermal dilutional testing or epidermal prick testing. Six patients who were diagnosed with skin abnormalities or uncontrolled asthma, or who were unable to discontinue antihistamines, were tested using in vitro radioallergosorbant testing (ImmunoCAP; Phadia; Portage, Mich.).
Th e vast majority of patients in the cohort (35 of 38; phase began with the weakest dilution vial. From this vial, drops were placed under the tongue once daily.
Patients were instructed to hold the drops under the tongue for 2 carefully timed minutes, aft er which they swallowed. Th e treatment schedule began with a single drop on day 1 and escalated by one drop each day for 5 days. On days 6 and 7, patients repeated 5 drops daily. On day 7, patients then transitioned to the next strongest dilution vial and decreased the dosage to 1 drop of the new vial on the fi rst day, which was equivalent to 5 drops of the previous vial. Th is, plus the repetition of 5 drops on days 6 and 7, added an extra measure of safety during the escalation period. Additionally, repeating 5 drops daily on days 6 and 7 was done to simplify the escalation schedule for patients as it allowed patients to progress to the next vial on the same day each week. Th e progression noted above was followed through each of the subsequent escalation vials until the maintenance dose was reached. Once the maintenance dose was reached, patients were allowed to adjust their dose between 1 and 5 drops, depending on their symptoms, with the goal being maintenance on the fewest number of drops that provided symptom control (fi gure 1). Once patients adjusted to a maintenance dose, they were encouraged to maintain that dose for the duration of treatment. Typically, patients with endpoints of 6 reached maintenance dosing in 4 to 6 weeks. Patients with less severe endpoints reached maintenance dosing even more rapidly.
At baseline and in the immediate post-escalation phase of treatment, patients completed a 6-item Allergy Medication Use Survey (AMUS) and the m-RQLQ, 9 a previously validated, 14-item, forced-choice Likert-type questionnaire. Post-escalation surveys were completed at the patient's fi rst visit aft er escalation was completed, typically 5 weeks after beginning SLIT. A subset of patients (n = 24) also completed questionnaires during the maintenance phase of treatment.
Maintenance data used for this study were collected at the most recent clinical follow-up visit for each patient. Items assessed on the AMUS were frequency of use in the last week for nasal steroids, nonsteroidal nasal sprays, oral corticosteroids, antihistamines, leukotriene inhibitors, and ophthalmic drops. Medication use was scored tallying 1 point for locally administered drugs (nasal sprays and eye drops) and 2 points for systemically administered drugs (oral steroids, antihistamines, and leukotriene inhibitors), as previously described. 11 Th e m-RQLQ included the eff ect of allergy symptoms on regular and recreational activities, sleep, sneezing, nose rubbing, nose blowing, stuff y nose, runny nose, itchy eyes, sore eyes, watery eyes, tiredness, thirst, and irritability. Patients rated each item considering only the previous 7 days, on a 0-to 6-point scale. A total m-RQLQ score was calculated by adding the scores of the individual domains together. Statistical analysis was performed by repeated-measures ANOVA for the group, with 3 time points assessed (baseline, post-escalation, and maintenance). Tukey post-hoc analysis specifi cally denoted statistically signifi cant time points following repeated-measures ANOVA. For the group with 2 time points assessed (baseline and post-escalation), statistical analysis was performed by two-tailed t tests. Statistical signifi cance was designated as p < 0.05.
Allergy testing
Antigen A-EP4 Antigen B-EP5 Antigen C-EP6
Highest test EP=6
All (+) antigens included in treatment vials, based on test EP of 6.
Treatment vial preparation Initial treatment vial: #4 dilution (2 concentrations higher than the hightest EP) for all (+) antigens.
Subsequent treatment vials:
5-fold stronger dilutions.
Initial treatment vial
Daily escalation of sublingual dosing from 1-5 drops.
Subsequent treatment vials
Transition to next stronger dilution, decrease drop dose to 1 drop on first day of new vial. 
Maintainance vials

Results
Escalation phase. Paired m-
All baseline m-RQLQ and AMUS surveys were completed prior to initiating SLIT therapy. Follow-up m-RQLQ and AMUS assessments were completed at a mean post-escalation timing of 5.5 weeks (range, 2 to 12). For the 38 patients with baseline and post-escalation data available, paired m-RQLQ scores revealed statistically signifi cant (p < 0.05) improvement in 6 of 14 domains. Domains in which improvement was seen included impact of allergy symptoms on recreational activities, sleep, nose rubbing, nose blowing, stuff y nose, and runny nose. Domains for itchy eyes and sore eyes approached signifi cance at p = 0.06 and p = 0.05, respectively. Total m-RQLQ score, which was a mean of all assessed domains, also showed a statistically signifi cant improvement (p < 0.05) of 28%, with a decrease from 2.2 at baseline to 1.6 aft er escalation. Paired data from the AMUS for 37 members of this group showed no signifi cant change in allergy medication use. Continued SLIT therapy demonstrated that a comparison of baseline to maintenance time points showed signifi cantly improved symptom scores in 5 domains (p < 0.05) (fi gure 2). Th e improved domains were recreational activities, sleep, rubbing nose, itchy eyes, and sore eyes. In addition, the total m-RQLQ score showed a statistically signifi cant (p < 0.05) improvement of 34% from baseline to maintenance phase (2.05 to 1.4).
AMUS data results for this subset with maintenance data available showed a statistically signifi cant reduction in the use of nasal steroids at both baseline and post-escalation time points as compared to maintenance time points (p < 0.05). No signifi cant change was noted R e g a c t R e c a c t S l e e p R u b n o s e B l o w n o s e S n e e z e S t u f f y R u n n y I t c h y e y e s S o r e e y e s W a t e r y e y e s
T i r e d T h i r s t y I r r i t a b l e T O T A L m-RQLQ score Domain
Baseline Post-Escalation Maintenance
Figure 2. Th is graph depicts post-escalation and maintenance m-RQLQ scores for the symptom domains (Reg act = regular activities; Rec act = recreational activities).
in any other of the medication classes measured by this survey.
Discussion
Effi cacy. Two large multicenter, double-blind, placebocontrolled trials to assess the effi cacy of SLIT in controlling symptoms of adult rhinoconjunctivitis have shown encouraging results. In a study of 634 patients with grass pollen allergy, a 30% reduction in symptom score and a 38% reduction in medication use were reported. 12 Th ese reductions were statistically signifi cant when compared to the results for the placebo group.
Another trial with a larger cohort of 855 grass pollen allergy patients showed a statistically signifi cant dosedependent reduction in medication use and improved quality of life scores for SLIT patients, as compared to a placebo group. 13 In addition, a meta-analysis of 10 double-blind, placebo-controlled pediatric allergic rhinitis SLIT trials reported improved symptom scores and decreased medication use for treated patients compared to placebo groups. 14 In fact, 30 of 36 studies reviewed at the time our study was conducted, comparing SLIT to a placebo or a control group, showed effi cacy in adults and children for rhinitis, conjunctivitis, and/or asthma. 15 Although such studies are encouraging, more U.S. SLIT trials are warranted, as noninjection immunotherapy is yet to be approved by the U.S. Food and Drug Administration.
Monotherapy versus polytherapy. Th e vast majority of published SLIT trials have been performed using a single treatment antigen. Although it examined the effi cacy of SLIT in polysensitized patients, a 2007 open-label study of 58 subjects compared results from patients receiving (1) monotherapy with grass pollen, (2) double-antigen therapy with grass plus birch pollen, (3) pharmacotherapy alone, and no treatment. 16 With regard to symptoms, medication scores, and nasal eosinophils, there was signifi cant improvement in the double-antigen SLIT group as compared to the singleantigen SLIT group at 2 years and then at 4 years vs. baseline. Th e improvements were seen both within and outside the treatment antigen target seasons.
Similar studies looking at the eff ects of combination antigen therapy are lacking. Th us far, our study appears to be the only SLIT trial that investigates the eff ects of polytherapy in both the escalation and the maintenance phases of treatment.
Safety. Acceptance of SLIT in the United States, particularly by the Food and Drug Administration, may be furthered by its high safety profi le. Since initiating SLIT at MUSC approximately 6 years ago, no serious adverse events have been associated with this form of treatment. In their review of 36 publications that reported on clinical trials using SLIT, Leatherman et al noted that no life-threatening or severe adverse events associated with SLIT have been reported. 15 Earlier reports described 2 cases of anaphylaxis possibly associated with SLIT. 17, 18 Th e fi rst involved a patient who experienced generalized pruritis, extremity edema, dyspnea, and dizziness on the second day of at-home SLIT polytherapy for inhalant allergies. 17 Patients in that study underwent polytherapy. (Although a broad range of antigens have been used in the current clinical trials, most have been investigated as monotherapy.) Th e second case involved a patient on rush SLIT dosing for latex allergy who developed anaphylactic shock upon reaching the maximum scheduled dose. 18 Despite these two reports, an excellent safety profi le for SLIT remains in comparison to the global incidence of severe adverse reactions with SCIT, which is 0.5 to 5.6%. 19 A high safety profi le for SLIT has also been shown in clinical trials for children <5 years of age. 20 Th e two reports of severe systemic reactions possibly related to SLIT seem to indicate that although previous SLIT studies have lacked evidence of life-threatening adverse events, the potential for severe systemic reactions should still be considered. 17, 18 Typically, the most common side eff ects associated with SLIT are mild and are described as oral itching and gastrointestinal symptoms. 19 Other adverse eff ects such as dry throat, throat irritation, and rhinitis have been reported. 12, 13, [21] [22] [23] [24] [25] Although such symptoms are oft en transient and drop-out rates are low, they are the most commonly cited reasons for discontinuation of SLIT. 15 Since initiation of SLIT at MUSC, 2 patients (not in this study cohort) have discontinued therapy because of mild adverse eff ects possibly due to SLIT treatment. Th e fi rst complained of sublingual discomfort and oral ulcers upon reaching her third week of escalation. Clouding the clinical picture, this patient also harbored herpes simplex virus. Although she attempted to do so twice, the patient could not complete escalation. Th e second patient who discontinued SLIT did so for a sensation of tongue and jaw fullness, which could not be objectively noted upon her physical examination. Th is patient also attempted escalation twice but dropped out before completion of the escalation phase.
Patients should be counseled regarding the possibility of such side eff ects before the initiation of SLIT. Th e low incidence of side eff ects at MUSC may be because of the escalation phase being spread over 2 to 5 weeks and because of the maintenance dosing used. Others have reported side eff ects of oral pruritis and mouth edema as high as 46% when using higher maintenance doses and no escalation phase.
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Escalation. Among the current published trials, there is no standard length for antigen titration. In a study by Dahl et al, patients did not actually undergo an escalation phase; rather, they began treatment with a one-dose grass antigen tablet, and the incidence of oral pruritis was 46%. 12 Patients in our study reached the maintenance phase of SLIT at an average of 5.5 weeks, which is consistent with the majority of the published SLIT studies.
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Dosing. As with escalation, there is great disparity regarding SLIT dosing quantities and schedules in the current literature. In a 2005 meta-analysis of 22 studies, which included both children and adults undergoing SLIT by drops and by tablets, it was impossible to determine the dose in micrograms of the major allergens used. 26 When SLIT was instituted in the MUSC Rhinology Division, there was a concern that a higher incidence of side eff ects might be more likely to occur using the high end of the dosing range, which had been reported to be eff ective at 3 to 375 times the dose of SCIT. 27 In 2006, Didier suggested only high-dose regimens (at least 50 to 100 times more than SCIT) should be used so that an adequate supply of allergen would be taken in by sentinel dendritic cells in the oral mucosa to induce "a strong and long-lasting T-cell response. " 28 In our study, the polytherapy dosing regimen during the maintenance phase was approximately 10 times greater than classic otolaryngic SCIT dosing during maintenance. During the escalation phase used in our study, the dosing regimen was approximately 250 times greater than classic otolaryngic SCIT dosing during the fi rst 4 to 5 weeks of immunotherapy.
Fortunately, because there is such a broad range of dosing currently being used, it now appears that safety and effi cacy are maintained regardless of the dosing regimen. Th is seems to be true even as it is diffi cult to make any defi nite dosing recommendations for SLIT because of the inconsistencies in dosing among the clinical trials. More double-blind, placebo-controlled studies are needed to determine the appropriate dosing regimen for SLIT. However, it is encouraging that patients in our study who Several subgroups ranging in size from approxiamately 300 to 700 patients showed a signifi cant reduction (p < 0.01) in "antiallergic medication. " Th is signifi cance was seen in both children and adults, and in groups undergoing treatment for a duration of 6 months or greater. Our study demonstrated a reduction in one antiallergy medication, nasal steroid sprays, during the maintenance phase of treatment. Th is is encouraging, but a possible disadvantage of our study may be related to the questionnaires, which were taken at a maximum of three time points and asked patients to report answers based on how they felt in the previous 7 days. Obtaining daily diary symptom and medication-use scores in addition to collecting time-point symptom and medication-use questionnaires in the clinic might have been more effective for discerning the true quality-of-life and allergy medication-use outcomes.
Additionally, 36 of our 38 patients were polysensitized, with the majority being sensitized to both seasonal and perennial antigens. Patient enrollment took place during all four seasons during 3 separate years. Unfortunately, this introduces variability. Nevertheless, some study patients would have been entering their most bothersome allergy seasons during the escalation and maintenance time points of the study, while others would have been entering their least bothersome seasons during the escalation and maintenance time points. Th is likely provided an overall balance regarding the eff ect of pollination during each season on individual subject symptom and medication-use scores.
Although there was no control group in this study, most of the subjects had previously experienced untreated allergies followed by failed avoidance measures and pharmacotherapy. Th e MUSC Rhinology Division is currently conducting a double-blind, placebo-controlled trial to confi rm the encouraging, yet early, results of our study.
In conclusion, our study demonstrates a statistically signifi cant improvement in allergic rhinitis symptoms in the immediate post-escalation phase of polytherapy SLIT with no signifi cant side eff ects. It also shows that signifi cant symptom improvements continue into the maintenance phase of treatment. Finally, it demonstrates a signifi cant reduction in patient use of nasal steroid sprays during the maintenance phase of treatment.
Further clinical studies regarding the time frame for clinical improvement with SLIT are needed. Double-blind, placebo-controlled studies evaluating several other aspects of SLIT, such as immunology, dosing, and rate of antigen titration, reduction of allergy medication use, effi cacy, and safety are also in demand. Great strides have been made in the realm of immunotherapy for allergic rhinitis since it was fi rst implemented almost 100 years ago. By continuing to analyze clinical outcomes for SLIT and by designing future studies in this arena, the MUSC Rhinology Division hopes to contribute to the global acceptance of SLIT as a viable immunotherapeutic choice.
